Meta-analysis: Castle Biosciences’ DecisionDx-Melanoma Test Accurately Stratifies Patients based on Risk of Recurrence and Metastasis
Castle Biosciences’ DecisionDx-Melanoma test consistently stratifies patients into risk groups with significantly different outcomes, according to a new independent meta-analysis in Cancers. For the study, the authors evaluated peer-reviewed articles that analyzed DecisionDx-Melanoma risk class data alongside at least one survival-based metric with a minimum of three years of follow-up. Systematic reviews, meta-analyses, and studies without […]